AVANIR Pharmaceuticals (FRA:AV2B) Price-to-Tangible-Book : 13.12 (As of May. 21, 2024)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-05-21), AVANIR Pharmaceuticals's share price is €14.37. AVANIR Pharmaceuticals's Tangible Book per Share of Sep. 2014 for the quarter that ended in Sep. 2014 was €1.10. Hence, AVANIR Pharmaceuticals's Price to Tangible Book Ratio of today is 13.12.

The historical rank and industry rank for AVANIR Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

During the past 13 years, AVANIR Pharmaceuticals's highest Price to Tangible Book Ratio was 67.24. The lowest was 0.00. And the median was 11.00.

FRA:AV2B's Price-to-Tangible-Book is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.4
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, AVANIR Pharmaceuticals's share price is €14.37. AVANIR Pharmaceuticals's Book Value per Sharefor the quarter that ended in Sep. 2014 was €1.10. Hence, AVANIR Pharmaceuticals's P/B Ratio of today is 13.12.

AVANIR Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for AVANIR Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals Price-to-Tangible-Book Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

Price-to-Tangible-Book

Get a 7-Day Free Trial

10.25

5.29

12.63

34.31

8.57

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Price-to-Tangible-Book	Get a 7-Day Free Trial															34.31	53.86	20.91	13.59	8.57

Competitive Comparison of AVANIR Pharmaceuticals's Price-to-Tangible-Book

For the Drug Manufacturers - Specialty & Generic subindustry, AVANIR Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AVANIR Pharmaceuticals's Price-to-Tangible-Book Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AVANIR Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where AVANIR Pharmaceuticals's Price-to-Tangible-Book falls into.

AVANIR Pharmaceuticals Price-to-Tangible-Book Calculation

AVANIR Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Sep. 2014 )
	=	14.37	/	1.095
	=	13.12

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

AVANIR Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » Price-to-Tangible-Book

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines